EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

Rongrong Zhao, Ziwen Pan, Jiawei Qiu, Boyan Li, Yanhua Qi, Zijie Gao, Wei Qiu, Weijie Tang, Xiaofan Guo, Lin Deng, Gang Li iD, Hao Xue

Cancer Communications · 2025-06 · 45 (6) · 677-701

DOI: 10.1002/cac2.70016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 14.03.2025. Verfasst von Rongrong Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan,…. Hauptthemen laut MEDLINE: Glioblastoma, Tumor-Associated Macrophages, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Jinan Science and Technology Bureau of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM. This study aimed to dissect the molecular mechanisms of specific immunosuppressive subpopulations to drive anti‐PD‐1 resistance in GBM.

Methods

We systematically analysed single‐cell RNA sequencing and spatial transcriptomics data from GBM tissues receiving anti‐PD‐1 therapy to characterize the microenvironment alterations. The biological functions of a novel circular RNA (circRNA) were validated both in vitro and in vivo. Mechanically, co‐immunoprecipitation, RNA immunoprecipitation and pull‐down assays were conducted.

Results

Mesenchymal GBM (MES‐GBM) cells, which were associated with a poor prognosis, and secreted phosphoprotein 1 (SPP1) + myeloid‐derived macrophages (SPP1 + MDMs), a unique subpopulation of MDMs with complex functions, preferentially accumulated in non‐responders to anti‐PD‐1 therapy, indicating that MES‐GBM cells and SPP1 + MDMs were the main anti‐PD‐1‐resistant cell subpopulations. Functionally, we determined that circular RNA succinate dehydrogenase complex assembly factor 2 (circSDHAF2), which was positively associated with the abundance of these two anti‐PD‐1‐resistant cell subpopulations, facilitated the formation of a regional MES‐GBM and SPP1 + MDM cell interaction loop, resulting in a spatially specific adaptive immunosuppressive microenvironment. Mechanically, we found that circSDHAF2 promoted MES‐GBM cell formation by stabilizing the integrin alpha 5 (ITGA5) protein through N‐glycosylation. Meanwhile, the N‐glycosylation of the ITGA5 protein facilitated its translocation into exosomes and subsequent delivery to MDMs to induce the formation of SPP1 + MDMs, which in turn maintained the MES‐GBM cell status and induced T‐cell dysfunction via the SPP1‐ITGA5 pathway, ultimately promoting GBM immune escape. Importantly, our findings demonstrated that antibody‐mediated ITGA5 blockade enhanced anti‐PD‐1‐mediated antitumor immunity.

Conclusions

This work elucidated the potential tissue adaptation mechanism of intratumoral dynamic interactions between MES‐GBM cells, MDMs and T cells in anti‐PD‐1 non‐responders and identified the therapeutic potential of targeting ITGA5 to reduce anti‐PD‐1 resistance in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor-Associated MacrophagesProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsBrain NeoplasmsHumansAnimalsMiceTumor MicroenvironmentCell Line, TumorRNA, CircularDrug Resistance, NeoplasmXenograft Model Antitumor AssaysIntegrins

Stichwörter der Autor:innen

Anti‐PD‐1 therapyN‐glycosylationexosomesglioblastomaintergrinstumor‐associated macrophages

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsITGA5 protein, humanPDCD1 protein, humanRNA, CircularIntegrins

Autor:innen und Institutionen

  • Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, P. R. China.
  • Shandong Key Laboratory of Brain Health and Function Remodeling, Jinan, P. R. China.
  • Department of Neurology, Loma Linda University Health, Loma Linda, California, USA.

ORCID-Profile: Gang Li

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Jinan Science and Technology Bureau of Shandong Province
  • Natural Science Foundation of Shandong Province of China
  • Taishan Pandeng Scholar Program of Shandong Province
  • Youth Taishan Scholar Program of Shandong Province

Zitieren

APA

Zhao, R., Pan, Z., Qiu, J., Li, B., Qi, Y., Gao, Z., Qiu, W., Tang, W., Guo, X., Deng, L., Li, G., & Xue, H. (2025). Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages. Cancer Communications, 45(6), 677-701. https://doi.org/10.1002/cac2.70016

Vancouver

Zhao R, Pan Z, Qiu J, Li B, Qi Y, Gao Z, et al. Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages. Cancer Communications. 2025;45(6):677-701. doi:10.1002/cac2.70016

BibTeX
@article{Zhao2025,
  author = {Zhao, Rongrong and Pan, Ziwen and Qiu, Jiawei and Li, Boyan and Qi, Yanhua and Gao, Zijie and Qiu, Wei and Tang, Weijie and Guo, Xiaofan and Deng, Lin and Li, Gang and Xue, Hao},
  title = {Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {6},
  pages = {677--701},
  doi = {10.1002/cac2.70016}
}
Kostenlos starten →